Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Trial Profile

A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasiglucagon (Primary)
  • Indications Congenital hyperinsulinism
  • Focus Registrational; Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 01 Nov 2023 Results evaluating the efficacy and safety of dasiglucagon in children with CHI and persistent hypoglycaemia as add-on to standard of care (SoC), published in the Journal of Clinical Endocrinology and Metabolism.
    • 30 Aug 2023 According to a Zealand Pharma media release, to ensure the most efficient regulatory process, the review by the US FDA will be conducted in two parts under NDA. Part 1 relates to dosing for up to 3 weeks, whereas Part 2 relates to use beyond 3 weeks; The PDUFA date for Part 2 will be set following submission of additional analyses from existing datasets requested by the US FDA, which is expected before the end of the year.
    • 30 Aug 2023 According to a Zealand Pharma media release, US FDA has granted priority review designation to dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing with a Prescription Drug User Fee Act (PDUFA) date on December 30, 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top